Fig. 6
From: Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis
Global G3/G4 toxicity analysis. Figure shows the G3/G4 toxicity analysis for all the selected trials. Nivolumab monotherapy was favored compared to the combination. Random effect model—Significant heterogeneity (P = 0.003). *Nivolumab 3 mg + ipilimumab 1 mg **Nivolumab 1 mg + ipilimumab 3 mg